{"id":995076,"date":"2026-08-13T16:04:59","date_gmt":"2026-08-13T20:04:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-second-quarter-2026-financial-results-and-provides-business-update\/"},"modified":"2026-08-13T16:04:59","modified_gmt":"2026-08-13T20:04:59","slug":"nucana-reports-second-quarter-2026-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-second-quarter-2026-financial-results-and-provides-business-update\/","title":{"rendered":"NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n
\n Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Advancing Additional Indications and Combination Strategies for NUC-7738<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Cash Runway Expected to Extend into 2029<\/em>
\n <\/strong>\n <\/p>\n

EDINBURGH, United Kingdom, Aug. 13, 2026 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (\u201cNuCana\u201d or the \u201cCompany\u201d) today announced financial results for the second quarter ended June 30, 2026 and provided an update on its clinical development program with its two lead anti-cancer medicines.<\/p>\n

\u201cNuCana continues to build momentum as we advance NUC-7738 closer to several important clinical and regulatory milestones,\u201d said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. \u201cWe are pleased to announce that recruitment is now complete in our Phase 2 NuTide:701 expansion study evaluating NUC-7738 in combination with Keytruda\u00ae<\/sup> (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma. Based on the data presented to date, we remain confident in the benefit NUC-7738 may offer these patients, and we remain on track to present final data from this study later this year. Following the Investigational New Drug application (\u201cIND\u201d) clearance from the U.S. Food and Drug Administration (the \u201cFDA\u201d) earlier this year, we look forward to continuing our dialogue with the FDA to determine the optimal path toward a potential registrational strategy for NUC-7738 in melanoma.\u201d<\/p>\n

Mr. Griffith continued, \u201cWe believe NUC-7738’s ability to disrupt RNA polyadenylation and act on multiple aspects of the tumor microenvironment could make an impact across a broad range of tumor types. The Company continues to assess potential additional indications, subject to emerging data and portfolio prioritization.\u201d<\/p>\n

Mr. Griffith concluded, \u201cNone of this progress would be possible without a strong financial foundation. With cash resources anticipated to fund our operations into 2029, we have the flexibility to keep advancing our pipeline, including evaluating additional indications and combination strategies for NUC-7738 and NUC-3373. We look forward to delivering on our milestones over the remainder of 2026.\u201d<\/p>\n

\n 2026 Anticipated Milestones<\/strong>\n <\/p>\n